• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    11/18/24 7:30:00 AM ET
    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer.

    "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvable doxorubicin-containing microneedle array (D-MNA) to treat non melanoma skin cancer, especially basal cell carcinoma."

    Dr. Mehmud brings over 20 years of global experience as a senior medical executive in clinical development, medical affairs, and drug safety across various therapeutic areas, including oncology, hematology, rare diseases, and primary care. He has played a central role in multiple successful launches of new medicines and has spearheaded innovative global medical lifecycle management strategies including for small molecules, antibodies, cell therapies and cytotoxic chemotherapies. His expertise encompasses late-phase development, product launch, and the seamless integration of new therapies into treatment pathways, all with a focus on improving patient outcomes through forward thinking clinical development plans. Dr. Mehmud's career includes senior roles at leading pharmaceutical companies such as Sanofi, Novartis, Bristol Myers Squibb (BMS), Pfizer, and GlaxoSmithKline (GSK) based in London, Paris and Philadelphia.

    Most recently, Dr. Mehmud was the Senior Vice President, Data Generation and Scientific Communications in Worldwide Global Medical Affairs at GlaxoSmithKline (LSE/NYSE:GSK), which included leadership of medical affairs sponsored and supported, interventional and non-interventional clinical trials. Before GSK, Dr. Mehmud was with Pfizer Inc., where he served in various roles including as Vice President and Worldwide Medical Franchise Head for Precision Medicine and Early Oncology Development, advancing the precision medicine oncology portfolio in a variety of tumor types, and supporting early-stage oncology projects moving from early clinical development to full development and market readiness, effectively bridging scientific innovation with commercial strategy.

    Dr. Mehmud has also held leadership roles at Bristol Myers Squibb, including as Vice President in global drug safety, where he oversaw the safety risk management of complex therapies, including antibody-based treatments and cellular therapies.

    Dr. Mehmud completed a medical degree from the University of Cambridge, as well as diplomas in internal medicine and pharmaceutical medicine from the Royal College of Physicians and holds a medical license with the UK General Medical Council.

    The company also announced the promotion of Edward J. Brennan, MD, FACS, to Chief Scientific Officer and Head of R&D program. Dr. Brennan, who was mostly recently the company's Chief Medical Officer, is a veteran pharmaceutical industry leader with extensive experience in all phases of clinical development across multiple therapeutics areas.

    "Dr. Brennan, as a co-founder of the company, has been instrumental in identifying our lead asset D-MNA and designing the clinical development program to position us to not only become the first in class but also the best-in-class novel therapeutic alternative to treat BCC," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Ed is an accomplished biopharmaceutical executive and his elevation to the role of Chief Scientific officer is very timely as we strengthen our executive team and gallop forward our D-MNA phase 2 study."

    Dr. Brennan has over 30 years of drug development experience. He has held senior medical leadership roles at major companies, including Wyeth, GlaxoSmithKline, and IndiPharm. As Medical Director at Wyeth and GSK, Dr. Brennan led clinical development programs that resulted in 10 FDA drug approvals. He oversaw teams responsible for all phases of clinical research as well as interactions with regulatory authorities. His therapeutic expertise includes Immunology, Oncology, Women's Health, and Genetic Diseases. Before industry roles, Dr. Brennan practiced medicine as a general surgeon.

    Dr. Brennan received his undergraduate Bachelor of Science Degree in Pharmacy from Philadelphia College of Pharmacy and Science. He went on to study Medicine at the Royal College of Surgeons in Ireland before receiving his medical degree from Temple University School of Medicine.

    For further information contact:

    Carolyn Bonner, President

    (610) 636-0184

    [email protected]

    Jeremy Feffer

    LifeSci Advisors

    (212) 915-2568

    [email protected]

    About Medicus Pharma Ltd:

    Medicus Pharma Ltd. (NASDAQ:MDCX, TSXV:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.

    SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company submitted a Phase 2 IND clinical protocol to the FDA in January 2024 for a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) that is expected to randomize up to 60 patients. The study is designed to evaluate the efficacy of two dose of two dose levels (100 and 200 ug) of D-MNA compared to placebo (P-MNA) in subjects with nodular BCC. Patient recruitment is currently underway in nine sites across the United States.

    Cautionary Notice on Forward-Looking Statements

    Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's plans and expectations concerning its business and operations, financial performance, strategic initiatives, product development, and the leadership transition. Forward-looking statements are often but not always, identified by the use of such terms as "may", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions.

    These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on SEDAR+ and on EDGAR, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Readers are cautioned that the foregoing list is not exhaustive and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



    Primary Logo

    Get the next $GSK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GSK
    $MDCX

    CompanyDatePrice TargetRatingAnalyst
    GSK plc
    $GSK
    6/3/2025Buy → Hold
    Berenberg
    GSK plc
    $GSK
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    GSK plc
    $GSK
    2/12/2025Equal-Weight
    Morgan Stanley
    GSK plc
    $GSK
    11/15/2024Buy → Hold
    Deutsche Bank
    GSK plc
    $GSK
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    GSK plc
    $GSK
    10/31/2024Buy → Neutral
    Guggenheim
    GSK plc
    $GSK
    7/8/2024Buy → Neutral
    UBS
    GSK plc
    $GSK
    5/30/2024$47.00Neutral
    Goldman
    More analyst ratings

    $GSK
    $MDCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GlaxoSmithKline downgraded by Berenberg

      Berenberg downgraded GlaxoSmithKline from Buy to Hold

      6/3/25 7:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $MDCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Raju Ajay

      4 - Medicus Pharma Ltd. (0001997296) (Issuer)

      7/24/25 5:19:38 PM ET
      $MDCX
    • SEC Form 4 filed by Chief Financial Officer Quinlan James P.

      4 - Medicus Pharma Ltd. (0001997296) (Issuer)

      7/24/25 5:17:18 PM ET
      $MDCX
    • SEC Form 4 filed by Chief Medical Officer Mehmud Faisal

      4 - Medicus Pharma Ltd. (0001997296) (Issuer)

      7/24/25 5:16:15 PM ET
      $MDCX

    $GSK
    $MDCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

      Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPDAdditional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completionJIANGSU, China, July 27, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE:GSK) to develop up to 12 innovative medicines, adding significant value to the globalization strategy of Hengrui and significant new growth opportunities to GSK beyond 2031. The programmes were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for the

      7/27/25 9:53:00 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults

      GSK and the National Senior Games team up to spotlight RSV risk, prevention, and the power of proactive health conversations National TV special "Redefining Aging" to launch in September, spotlighting Senior Games athletes and their experiences with RSV GSK plc (LSE/NYSE:GSK) announced its sponsorship of the 2025 National Senior Games as part of its nationwide Sideline RSV campaign, a health education campaign aimed at helping educate older adults and their loved ones about the risks of respiratory syncytial virus, or RSV. The National Senior Games give adults over 50 across the US the opportunity to stay engaged and active in competitive sports like basketball and swimming, providin

      7/24/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation

      Prefilled syringe presentation offers a convenient administration option to healthcare professionals An estimated one million people develop shingles in the US each year1 GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster). The new prefilled syringe removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process for healthcare professionals. The existing vaccine presentation consists of two vials, a lyophilized (powder) antigen and a liquid adjuvant,

      7/17/25 7:00:00 AM ET
      $AGEN
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $GSK
    $MDCX
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      7/30/25 11:07:38 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medicus Pharma Ltd. filed SEC Form 8-K: Other Events

      8-K - Medicus Pharma Ltd. (0001997296) (Filer)

      7/30/25 6:57:06 AM ET
      $MDCX
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      7/30/25 6:25:49 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $MDCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GSK plc

      SC 13G/A - GSK plc (0001131399) (Subject)

      11/12/24 4:32:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by GSK plc (Amendment)

      SC 13G/A - GSK plc (0001131399) (Subject)

      2/13/24 1:37:25 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by GSK plc (Amendment)

      SC 13G/A - GSK PLC (0001131399) (Subject)

      2/14/23 1:54:01 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $MDCX
    Leadership Updates

    Live Leadership Updates

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

      TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

      11/18/24 7:30:00 AM ET
      $GSK
      $MDCX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $MDCX
    Financials

    Live finance-specific insights

    See more
    • Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

      Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include

      8/6/24 4:05:00 PM ET
      $GSK
      $MYGN
      $PSNL
      $QGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Medical Specialities
    • GSK and CureVac to Restructure Collaboration into New Licensing Agreement

      GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA

      7/3/24 2:40:00 AM ET
      $CVAC
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Reports Third Quarter Fiscal 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of approximately 33% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes.Announced a non-exclusive data license with GSK plc (NYSE:GSK) for novel drug target discovery and other research. U

      2/7/24 4:01:00 PM ET
      $GSK
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care